This is an Acute Lung Injury SCCOR application designed to study the pathogenesis and treatment of early acute lung injury. Although considerable progress has been made in selected areas of research and treatment of clinical acute lung injury, the pathogenesis of clinical lung injury is incompletely understood and mortality remains too high. Clinical and basic research is needed to provide new knowledge regarding fundamental mechanisms of lung injury as well as to test new therapies for acute lung injury (ALl), an important cause of acute respiratory failure in critically ill patients. Project 1 proposes a randomized, double-blind, phase II clinical trial to evaluate the potential efficacy of activated protein C (APC) for the treatment of acute lung injury. This project will also explore mechanistically the contribution of coagulation and inflammation dependent mechanisms to clinical lung injury. Project 2 is a clinical project to investigate the interactions among human genetics, bacterial genetics, and host events in the development of acute lung injury from bacterial pneumonia. This project will test the potential contribution of Mannose Binding Lectin genetic abnormalities as a cause of severe pneumonia and acute lung injury. This project will also test the hypothesis that P.aeruginosa colonization transforms to lung infection (ventilator-associated pneumonia) when the P.aeruginosa strains express type III virulence genes. Project 3 will examine the contribution of coagulation dependent mechanisms in experimental lung injury in mice by studying genetically modified mice as well as testing the impact of recombinant mouse AP C as therapy for experimental lung injury. Project 4 will examine the role of transforming growth factor-beta1 as a pathogenetic mechanism for early experimental acute lung injury, evaluating the mechanisms for TGF-beta1 activation, and also will identify the mechanisms for responsible for the TGF-beta1 induced alterations in alveolar epithelial fluid transport. The administrative and clinical cores (Cores A & B) will support the scientific objective of the projects. The proteomics core (Core C) will provide innovative methods for identifying novel proteins in the bronchoalveolar lavage fluid from patients and animals with acute lung injury, both before and after several treatment strategies.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL074005-02
Application #
6804633
Study Section
Special Emphasis Panel (ZHL1-CSR-R (M1))
Program Officer
Harabin, Andrea L
Project Start
2003-09-30
Project End
2008-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
2
Fiscal Year
2004
Total Cost
$1,922,855
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Beitler, Jeremy R; Thompson, B Taylor; Matthay, Michael A et al. (2015) Estimating dead-space fraction for secondary analyses of acute respiratory distress syndrome clinical trials. Crit Care Med 43:1026-35
Pittet, Jean-François; Koh, Hidefumi; Fang, Xiaohui et al. (2013) HMGB1 accelerates alveolar epithelial repair via an IL-1?- and ?v?6 integrin-dependent activation of TGF-?1. PLoS One 8:e63907
Agrawal, Ashish; Zhuo, Hanjing; Brady, Sandra et al. (2012) Pathogenetic and predictive value of biomarkers in patients with ALI and lower severity of illness: results from two clinical trials. Am J Physiol Lung Cell Mol Physiol 303:L634-9
Fricks-Lima, J; Hendrickson, C M; Allgaier, M et al. (2011) Differences in biofilm formation and antimicrobial resistance of Pseudomonas aeruginosa isolated from airways of mechanically ventilated patients and cystic fibrosis patients. Int J Antimicrob Agents 37:309-15
Srinivasan, Ramya; Song, Yuanlin; Wiener-Kronish, Jeanine et al. (2011) Plasminogen activation inhibitor concentrations in bronchoalveolar lavage fluid distinguishes ventilator-associated pneumonia from colonization in mechanically ventilated pediatric patients. Pediatr Crit Care Med 12:21-7
Lynch, Susan V; Flanagan, Judith L; Sawa, Teiji et al. (2010) Polymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV - implications for anti-PcrV immunotherapy. Microb Pathog 48:197-204
Ware, Lorraine B; Koyama, Tatsuki; Billheimer, D Dean et al. (2010) Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 137:288-96
Roux, Jérémie; Carles, Michel; Koh, Hidefumi et al. (2010) Transforming growth factor beta1 inhibits cystic fibrosis transmembrane conductance regulator-dependent cAMP-stimulated alveolar epithelial fluid transport via a phosphatidylinositol 3-kinase-dependent mechanism. J Biol Chem 285:4278-90
Goolaerts, Arnaud; Roux, Jérémie; Ganter, Michael T et al. (2010) Serotonin decreases alveolar epithelial fluid transport via a direct inhibition of the epithelial sodium channel. Am J Respir Cell Mol Biol 43:99-108
Moskowitz, Samuel M; Wiener-Kronish, Jeanine P (2010) Mechanisms of bacterial virulence in pulmonary infections. Curr Opin Crit Care 16:8-12

Showing the most recent 10 out of 64 publications